EUVIMEDEUVIMED entdecken
Systematische Übersicht

The use of diflunisal for transthyretin cardiac amyloidosis: a review

Michel Ibrahim iD, Garly Rushler Saint Croix iD, Spencer Lacy iD, Michael Fattouh, Maria Irene Barillas-Lara, Leili Behrooz iD, Olivia Mechanic

Heart Failure Reviews · 2022-03 · 27 (2) · 517-524

DOI: 10.1007/s10741-021-10143-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Heart Failure Reviews, online erschienen am 16.07.2021. Verfasst von Michel Ibrahim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department Medicine, Division of Cardiovascular Medicine, Boston University Hospital, 801 Massachusetts Avenue Suite 400, Boston, MA, 02118, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Diflunisal. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. Diflunisal, an agent that stabilizes TTR, has been used as an off-label therapeutic for ATTR-CM. Given limited data surrounding the use of diflunisal, a systematic review of the literature is warranted. We searched the PubMed, MEDLINE, and Embase databases for studies that reported on the use of diflunisal therapy for patients with ATTR-CM. We included English language studies which assessed the effect of diflunisal in adult patients with ATTR-CM who received diflunisal as primary treatment and reported clinical outcomes with emphasis on studies that noted the safety and efficacy of diflunisal in cardiac manifestations of ATTR amyloidosis. We excluded studies which did not use diflunisal therapy or used diflunisal therapy for non-cardiac manifestations of TTR amyloidosis. We also excluded case reports, abstracts, oral presentations, and studies with fewer than 10 subjects. Our search yielded 316 records, and we included 6 studies reporting on 400 patients. Non-comparative single-arm small non-randomized trials for diflunisal comprised 4 of the included studies. The 2 studies that compared diflunisal versus no treatment found improvements in TTR concentration, left atrial volume index, cardiac troponin I, and global longitudinal strain. Overall, diflunisal use was associated with decreased mortality and number of orthotopic heart transplant in ATTR-CM patients. Although a smaller number of patients had to stop treatment due to gastrointestinal side effects and transient renal dysfunction, there were no severe reactions reported in the studies included in our review. This systematic review supports the use of diflunisal for ATTR-CM. Additional long-term analyses and randomized clinical trials are needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialDiflunisalAdultHumansMyocardiumPrealbumin

Stichwörter der Autor:innen

ATTR cardiac amyloidosisDiflunisalTransthyretin cardiac amyloidosis

Substanzen

PrealbuminDiflunisal

Autor:innen und Institutionen

  • Department Medicine, Division of Cardiovascular Medicine, Boston University Hospital, 801 Massachusetts Avenue Suite 400, Boston, MA, 02118, USA.
  • Division of Cardiology At Mount Sinai Medical Center, Columbia University, 4300 Alton Rd, Miami Beach, FL, 33140, USA.
  • Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Clinical Research Building, Miami, 33136, FL, USA.
  • Department of Internal Medicine Boston Medical Center, Boston University School of Medicine, 72 East Concord St, Boston, MA, 02118, USA.
  • Department Medicine, Division of Cardiovascular Medicine, Boston University Hospital, 801 Massachusetts Avenue Suite 400, Boston, MA, 02118, USA. Leili.behrooz@bmc.org.

ORCID-Profile: Michel Ibrahim, Garly Rushler Saint Croix, Spencer Lacy, Leili Behrooz

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ibrahim, M., Saint Croix, G. R., Lacy, S., Fattouh, M., Barillas-Lara, M. I., Behrooz, L., & Mechanic, O. (2022). The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Failure Reviews, 27(2), 517-524. https://doi.org/10.1007/s10741-021-10143-4

Vancouver

Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Failure Reviews. 2022;27(2):517-524. doi:10.1007/s10741-021-10143-4

BibTeX
@article{Ibrahim2022,
  author = {Ibrahim, Michel and Saint Croix, Garly Rushler and Lacy, Spencer and Fattouh, Michael and Barillas-Lara, Maria Irene and Behrooz, Leili and Mechanic, Olivia},
  title = {The use of diflunisal for transthyretin cardiac amyloidosis: a review},
  journal = {Heart Failure Reviews},
  year = {2022},
  volume = {27},
  number = {2},
  pages = {517--524},
  doi = {10.1007/s10741-021-10143-4}
}
Kostenlos starten →